SEK 0.04
(-10.26%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | - SEK | 0.0% |
2022 | - SEK | 0.0% |
2021 | - SEK | 0.0% |
2020 | - SEK | 100.0% |
2019 | -84.18 Thousand SEK | 0.0% |
2018 | -84.18 Thousand SEK | -28.85% |
2017 | -65.33 Thousand SEK | -10.64% |
2016 | -59.05 Thousand SEK | -1182.9% |
2015 | -4603.00 SEK | 93.57% |
2014 | -71.63 Thousand SEK | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | - SEK | 0.0% |
2024 Q2 | - SEK | 0.0% |
2023 Q3 | - SEK | 0.0% |
2023 Q2 | - SEK | 0.0% |
2023 Q1 | - SEK | 0.0% |
2023 Q4 | - SEK | 0.0% |
2023 FY | - SEK | 0.0% |
2022 Q4 | - SEK | 0.0% |
2022 Q1 | - SEK | 0.0% |
2022 Q2 | - SEK | 0.0% |
2022 Q3 | - SEK | 0.0% |
2022 FY | - SEK | 0.0% |
2021 Q4 | - SEK | 100.0% |
2021 FY | - SEK | 0.0% |
2021 Q1 | -21 Thousand SEK | 52.27% |
2021 Q2 | -21 Thousand SEK | 0.0% |
2021 Q3 | -21 Thousand SEK | 0.0% |
2020 Q4 | -44 Thousand SEK | -291.3% |
2020 FY | - SEK | 100.0% |
2020 Q3 | 23 Thousand SEK | 0.0% |
2020 Q1 | - SEK | 0.0% |
2020 Q2 | - SEK | 0.0% |
2019 Q2 | - SEK | 0.0% |
2019 Q4 | - SEK | 0.0% |
2019 Q3 | - SEK | 0.0% |
2019 FY | -84.18 Thousand SEK | 0.0% |
2019 Q1 | - SEK | 100.0% |
2018 Q3 | 21 Thousand SEK | 10.53% |
2018 Q4 | -3057.00 SEK | -114.56% |
2018 FY | -84.18 Thousand SEK | -28.85% |
2018 Q1 | 10 Thousand SEK | 0.0% |
2018 Q2 | 19 Thousand SEK | 90.0% |
2017 Q4 | - SEK | -100.0% |
2017 Q2 | 437 Thousand SEK | -42.58% |
2017 Q1 | 761 Thousand SEK | 0.0% |
2017 FY | -65.33 Thousand SEK | -10.64% |
2017 Q3 | 1.34 Million SEK | 206.86% |
2016 Q1 | - SEK | 0.0% |
2016 FY | -59.05 Thousand SEK | -1182.9% |
2016 Q2 | - SEK | 0.0% |
2016 Q4 | - SEK | 0.0% |
2016 Q3 | - SEK | 0.0% |
2015 Q2 | - SEK | 0.0% |
2015 Q3 | - SEK | 0.0% |
2015 Q4 | - SEK | 0.0% |
2015 FY | -4603.00 SEK | 93.57% |
2015 Q1 | - SEK | -100.0% |
2014 Q2 | - SEK | 0.0% |
2014 Q4 | 149 Thousand SEK | 0.0% |
2014 FY | -71.63 Thousand SEK | 0.0% |
2014 Q3 | - SEK | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AcuCort AB | 6.59 Million SEK | 100.0% |
AlzeCure Pharma AB (publ) | -476 Thousand SEK | 100.0% |
BioGaia AB (publ) | 950.19 Million SEK | 100.0% |
Enzymatica AB (publ) | 31.86 Million SEK | 100.0% |
Enorama Pharma AB (publ) | -3.9 Million SEK | 100.0% |
Klaria Pharma Holding AB (publ.) | -9000.00 SEK | 100.0% |
Moberg Pharma AB (publ) | -2.09 Million SEK | 100.0% |
Nanexa AB (publ) | 59.15 Million SEK | 100.0% |
Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | 100.0% |
ODI Pharma AB | -1.34 Million SEK | 100.0% |
Orexo AB (publ) | 549.9 Million SEK | 100.0% |
Probi AB (publ) | 220.21 Million SEK | 100.0% |
Swedencare AB (publ) | 164.8 Million SEK | 100.0% |
Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 100.0% |
Toleranzia AB | -919 Thousand SEK | 100.0% |
Vivesto AB | -10.65 Million SEK | 100.0% |